Aspen Neuroscience, Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 2, 2026, to register shares of common stock issuable under three employee benefit plans established in connection with the company's recent public offering.

Key Highlights

  • Three plans covered: The registration statement covers the Aspen Neuroscience, Inc. 2018 Stock Plan, the 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan.
  • Filing date: The S-8 was filed with the SEC on November 2, 2026.
  • Company status: Aspen Neuroscience, Inc. is identified in the filing as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • Incorporated prospectus: The filing incorporates by reference a prospectus dated October 29, 2026, related to the company's Form S-1 registration statement (No. 333-299393), which includes audited financial statements for the latest fiscal year.
  • Agent for service: Damien McDevitt, Ph.D., President and Chief Executive Officer, is named as the agent for service, located at 10835 Road to the Cure, Suite 100, San Diego, CA 92121.
  • Delaware incorporation: The registrant is incorporated in Delaware with I.R.S. Employer Identification Number 83-1312969.

Aspen Neuroscience Registers Equity Plans Following October 2026 IPO

According to the filing, Aspen Neuroscience, Inc. (NASDAQ:ASPE) registered shares of common stock under three equity compensation plans by filing a Form S-8 on November 2, 2026. The three plans named are the 2018 Stock Plan, the 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan. The S-8 enables the company to offer registered securities to employees and other plan participants under these arrangements.

The registration statement incorporates by reference several previously filed documents, including a prospectus filed pursuant to Rule 424(b) and dated October 29, 2026, which relates to the company's Form S-1 registration statement (No. 333-299393). The filing also incorporates by reference a Form 8-K filed by the registrant on November 2, 2026, and a description of the registrant's common stock contained in a Form 8-A (Registration No. 001-43526) filed on October 29, 2026. The company disclosed that any documents subsequently filed under Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act will also be automatically incorporated by reference, with certain exceptions for Form 8-K Items 2.02 and 7.01.

The filing describes indemnification provisions for directors and officers under the General Corporation Law of the State of Delaware, including Sections 102 and 145, as well as under the company's Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. According to the filing, the company's Charter provides that directors shall not be personally liable to the company or its stockholders for monetary damages for breaches of fiduciary duty, subject to exceptions required by Delaware law. The filing states that the company will indemnify directors, officers, and certain other indemnitees to the fullest extent permitted by Delaware law.

What Was Disclosed

Aspen Neuroscience, Inc. filed an S-8 registration statement on November 2, 2026, to register common stock issuable under its 2018 Stock Plan, 2026 Equity Incentive Plan, and 2026 Employee Stock Purchase Plan, incorporating by reference its October 2026 prospectus and related filings.